X
Price cut unlocks NICE nod for Perjeta in post-surgery breast cancer
https://pharmaphorum.com/news/price-cut-unlocks-nice-nod-for-perjeta-in-post-surgery-breast-cancer/
Perjeta
Roche’s Perjeta combo approved in Europe for early breast cancer
The European Commission (EC) has approved Roche’s Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy for post-surgery (adjuvant) treatment of adult patients with HER2-positive early breast cancer (eBC) at high risk of recurrence.